Compare Public Storage (PSA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Sanofi SA — how do they compare? Public Storage trades at $285.55 (market cap $53.35B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and Sanofi SA for 94 Days on average.
| PSA | SNY | |
|---|---|---|
Market Cap | $53.35B | $95.18B |
Volume | 1,176,034 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $52.34 |
52-Week Low | $258.44 | $39.51 |
Typical Hold Time | 130 Days | 94 Days |
Enterprise Value | $67.62B | $114.48B |
Dividend Yield | 4.2% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $281.99, down 1.35% on the day, with a bearish technical signal and mixed sentiment. The stock exhibits strong profitability with a 41.8% net income margin and consistent earnings beats, but faces headwinds from negative net cash flow trends. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million senior notes offering in the Canadian market, signaling expansion efforts.
PSA presents a cautious outlook with a consensus price target of $328.33 implying upside, yet technical indicators and cash flow concerns weigh. Investment opportunities lie in its high margins and dividend yield, while risks include operational execution amid interest rate sensitivity and competitive pressures in the REIT sector.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
